Editorial Board
Jump to navigation
Jump to search
Our editorial board is comprised of cancer experts, organized primarily by disease focus. If you are interested in getting involved, please feel free to contact us with any questions or inquiries, at contact @ hemonc.org.
Editor-in-Chief and Chief Executive Officer, HemOnc.org LLC
 |
Peter C. Yang, MD Boston, MA, USA |
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Chief Technology Officer, HemOnc.org LLC
 |
Jeremy L. Warner, MD, MS, FAMIA, FASCO Brown University Providence, RI, USA |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Lifespan Cancer Institute. He is a Professor of Medicine and Professor of Biostatistics at Brown University. He is the Director of the Brown/Lifespan Center for Clinical Cancer Informatics and Data Science (CCIDS). |
Deputy Editor
 |
Andrew J. Cowan, MD Seattle, WA, USA |
Dr. Cowan is board certified in Hematology and Medical Oncology; he is the Interim Clinical Director of the myeloma service at the Fred Hutch Cancer Center. He is an associate professor at the University of Washington. |
Associate Editors
| Cancer Registries | ||
|---|---|---|
 |
Mary Mesnard, BS, CTR |
Ms. Mesnard is a senior study director at Westat and was formerly with the State of Maryland's central cancer registry. |
| Evidence-based Oncology | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO, USA |
Dr. Schoen is board certified in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Pediatric Hematology/Oncology | ||
 |
Wayne H. Liang, MD, MS, FAMIA Emory University Atlanta, GA, USA |
Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University. |
| Radiation Oncology | ||
 |
Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA, USA |
Dr. Bitterman is board certified in Radiation Oncology; she practices at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. She is an Assistant Professor of Radiation Oncology at Harvard Medical School. |
| Supportive Oncology | ||
 |
Maryam B. Lustberg, MD, MPH Yale University New Haven, CT, USA |
Dr. Lustberg is board certified in Medicine and Medical Oncology; she is the director of the Breast Center at Smilow Cancer Hospital and chief of Breast Medical Oncology at Yale Cancer Center. She is an Associate Professor of Internal Medicine (Medical Oncology) at Yale University. She is the co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the 2022 president of the Multinational Association of Cancer Supportive Care (MASCC) |
Regional Associate Editors
| Asia | ||
|---|---|---|
| Europe and United Kingdom | ||
 |
Mark P. Lythgoe, MBBS, PharmD Imperial College London London, England, UK |
Dr. Lythgoe is a medical oncologist, clinical pharmacist, and health services researcher. His work involves analyzing cancer drug approvals and regulatory pathways. |
| North Africa and Middle East | ||
| Oceania | ||
 |
Georgina Kennedy, PhD Ingham Institute for Applied Medical Research Sydney, NSW, Australia |
Dr. Kennedy is a health data infrastructure specialist and data engineer. Her work involves harmonizing systemic anticancer therapy standards, including the eviQ resource of evidence-based, consensus driven cancer treatment protocols. |
| Latin America | ||
| Sub-Saharan Africa | ||
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
H. Deepika Fernandes, MD, FACP Tempe, AZ, USA |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the HonorHealth Virginia G. Piper Cancer Care Network. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA, USA |
Dr. Buchbinder is board certified in Medical Oncology; she is a senior physician at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Gastrointestinal Oncology, Intestinal | ||
 |
Travis Zack MD, PhD San Francisco, CA, USA |
Dr. Zack is a senior hematology/oncology fellow at the University of California, San Francisco. |
| Gastrointestinal Oncology, Extraintestinal | ||
 |
Eric I. Marks, MD Boston, MA, USA |
Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA, USA |
Dr. Khaki is board certified in Hematology and Medical Oncology; he practices at Stanford Health Care. He is a a Clinical Assistant Professor of Oncology at Stanford University School of Medicine. |
| Gynecologic Oncology | ||
 |
Alaina J. Brown, MD, MPH Nashville, TN, USA |
Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Assistant Professor of Obstetrics and Gynecology at Vanderbilt University. |
| Head & Neck Cancer | ||
 |
Jennifer H. Choe, MD, PhD Nashville, TN, USA |
Dr. Choe is board certified in Internal Medicine and Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center, where she is the Head and Neck Medical Oncology Disease Team Lead and directs the clinical trials research program in the Division of Hematology and Oncology within the Department of Medicine at Vanderbilt University Medical Center. She is an Assistant Professor of Medicine at Vanderbilt University and specializes in cancers of the head and neck, thyroid, and non-melanoma skin cancers. |
| Mesothelioma | ||
 |
Marjorie G. Zauderer, MD, MS, FACP New York, NY, USA |
Dr. Zauderer is board certified in Medical Oncology; she is co-director of the mesothelioma program at Memorial Sloan Kettering Cancer Center. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA, USA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a Clinical Professor of Neurology at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN, USA |
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA |
Dr. Kulkarni is board certified in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Ashwin Kishtagari, MD Vanderbilt University Nashville, TN, USA |
Dr. Kishtagari is board certified in Internal Medicine and Medical Oncology; he practices at Vanderbilt University Medical Center. He is an Assistant Professor of Medicine (Hematology/Oncology) at Vanderbilt University. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN, USA |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT, USA |
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA, USA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Samuel M. Rubinstein, MD University of North Carolina Chapel Hill, NC, USA |
Dr. Rubinstein is board certified in Hematology and Medical Oncology; he is a clinical assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN, USA |
Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
| Histiocytic Disorders | ||
 |
Gaurav Goyal, MBBS UAB Birmingham, AL, USA |
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at the O'Neal Comprehensive Cancer Center at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Blastomas & Extracranial Germ Cell Tumors | ||
 |
Elaine M. Fan, MD, MS Wichita, KS, USA |
Dr. Fan is an Assistant Professor of Pediatrics at the University of Kansas and practices at Wesley Medical Center. She is particularly interested in applying clinical informatics to improve clinical workflow efficiency, enhance provider and patient experience and, ultimately, improve health outcomes in pediatrics and pediatric hematology-oncology. Dr. Fan is board-certified in Pediatrics and board-eligible in Pediatric Hematology-Oncology. |
| Pediatric Leukemia & Lymphoma | ||
 |
David Noyd, MD, MPH University of Washington Seattle, WA, USA |
Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at Seattle Children's Hospital. He is an Assistant Professor of Pediatrics at the University of Washington. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
 |
Nicole M. Wood, DO University of Missouri Kansas City, MO, USA |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri. |
| Transplant | ||
 |
Talal Hilal, MD Mayo Clinic Phoenix, AZ, USA |
Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at Mayo Clinic Arizona. He is an assistant professor at the Mayo Clinic. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an Assistant Professor of Medicine (Hematology/Oncology) |
| Clinical Pharmacology | ||
 |
Austin Fitts, PharmD National Cancer Institute Silver Springs, MD, USA |
Dr. Fitts is a Postdoctoral Fellow at the National Cancer Institute. |
| Living Systematic Reviews | ||
 |
Irbaz Bin Riaz, MD, PhD, MS Mayo Clinic Phoenix, AZ, USA |
Dr. Riaz is board certified in Internal Medicine and Medical Oncology; he is an Assistant Professor of Medicine at Mayo Clinic, Arizona. |
Page Editors
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA, USA)
- Brianna Bakow, MD (Brigham and Women's Hospital, Boston, MA, USA)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY, USA)
- Michael J. Glover, MD (Stanford University, Palo Alto, CA, USA)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO, USA)
- Matthew Hadfield, DO (Lifespan/Brown University, Providence, RI, USA)
- C. Beau Hilton, MD (Vanderbilt University, Nashville, TN, USA)
- Shalin Kothari, MD (Yale University, New Haven, CT, USA)
- Mary L. Kwok, MD, FACP (Fred Hutch Cancer Center, Seattle, WA, USA)
- Emily A. Mann, MD (Boston University, Boston, MA, USA)
- Eric I. Marks, MD (Boston University, Boston, MA, USA)
- Francesca Montanari, MD (Yale University, New Haven, CT, USA)
- Ryan H. Nguyen, DO (University of Illinois at Chicago, IL, USA)
- Michael K. Rooney, MD (MD Anderson Cancer Center, Houston, TX, USA)
- Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX, USA)
- Leyre Zubiri, MD, PhD (Massachusetts General Hospital, Boston, MA, USA)
COI Disclosures
Please see our conflict of interest page for more details. Disclosures here are for COI within 24 months of the date of disclosure unless otherwise noted.
| Name | Research funding (to institution) | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Jon Arnason | Nothing to disclose | Speaker: Bristol-Myers Squibb | 2023-06-28 |
| Brianna Bakow | Nothing to disclose | Nothing to disclose | 2023-08-27 |
| Danielle S. Bitterman | Nothing to disclose | Nothing to disclose | 2023-08-03 |
| Alaina J. Brown | NIH | Nothing to disclose | 2022-08-03 |
| Elizabeth Buchbinder | NIH; Clinical trial support from Eli Lilly, Novartis, Checkmate Pharmaceuticals, Genentech/Roche, and Bristol-Myers Squibb. | Consulting as an advisory board member for Novartis, Instil Bio, Nektar, Xilio Therapeutics, Sanofi, Merck, Iovance Biotherapeutics; Employment (family member): Alexion Pharmaceuticals, Takeda. | 2023-08-03 |
| Jennifer H. Choe | Institutional research funding: Alx oncology, Merck Sharp & Dohme, Arcus Biosciences | Advisory Board and consulting: Eisai, Exelixis, Merck Sharp & Dohme, Coherus Biosciences | 2023-09-29 |
| Andrew Cowan | Abbvie, Nektar, Harpoon, Janssen, Adaptive, Sanofi, BMS, Celgene | Consultancy: Abbvie, BMS, Secura Bio, EUSA, GSK | 2024-03-04 |
| Elizabeth J. Davis | Trial funding: Karyopharm, Bristol Myers Squibb, Incyte, Actuate, InhibRx, Top Alliance BioSciences, Genentech, Five Prime Therapeutics | Consulting/Advisory Board: Deciphera, Aadi Honoraria: MJH Life Sciences Speakers' Bureau: Physicians' Education Resource |
2023-01-03 |
| Bhagirathbhai Dholaria | Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, NCI, Atara, Gilead, Molecular templates, BMS, AstraZeneca, Adicet | Consulting/Advisory Board: Janssen, Pluri Biotech, Boxer Capital; Consultation/travel funds: Ellipsis pharma, Lumanity, Autolus, Acrotech, ADC therapeutics | 2023-09-09 |
| Elaine Fan | Nothing to disclose | Consulting: Westat | 2023-09-09 |
| H. Deepika Fernandes | Nothing to disclose | Nothing to disclose | 2023-06-28 |
| Austin Fitts | Nothing to disclose | Consulting: Westat | 2023-01-03 |
| Teja Ganta | Nothing to disclose | Other: Epic Systems, Analog Devices | 2023-09-04 |
| Michael J. Glover | Nothing to disclose | Nothing to disclose | 2023-04-15 |
| Gaurav Goyal | NIH/NCI | Consultancy: 2nd.MD; Royalties: UpToDate Inc; Advisory Board: Opna Bio LLC, Seagen | 2023-09-10 |
| Laura Graham | Nothing to disclose | Nothing to disclose | 2023-09-11 |
| Matthew Hadfield | Nothing to disclose | Nothing to disclose | 2023-08-07 |
| Talal Hilal | NIH/NCI | Nothing to disclose | 2023-09-11 |
| C. Beau Hilton | Nothing to disclose | Nothing to disclose | 2023-10-03 |
| Ali R. Khaki | Janssen, 23andMe | Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME |
2023-09-01 |
| Ashwin Kishtagari | Nothing to disclose | Consulting/Advisory Board: CTI BioPharma | 2023-08-03 |
| Shalin Kothari | Nothing to disclose | Nothing to disclose | 2023-08-10 |
| Amit Kulkarni | Research Funding to Institution: Astra Zeneca | Consulting/Advisory Board: Genentech, Exelixis; Stock and Other Ownership Interests: Fate Therapeutics, Merck, Exact Sciences, Gilead Sciences, Mirati Therapeutics, Novavax. | 2023-08-03 |
| Mary L. Kwok | BeiGene | Nothing to disclose | 2023-06-28 |
| Wayne H. Liang | Nothing to disclose | Consulting/Advisory Board: Westat | 2021-11-10 |
| Maryam Lustberg | Nothing to disclose | Consulting/Advisory Board: Pfizer, Gilead, Novartis, Eli Lilly, AstraZeneca | 2023-07-04 |
| Mark P. Lythgoe | Nothing to disclose | Nothing to disclose | 2023-10-29 |
| Emily A. Mann | Nothing to disclose | Nothing to disclose | 2023-08-30 |
| Eric Marks | Research funding: Merck | Consulting/Advisory Board: Sermo, Medscape, Brand Institute, M3 | 2023-06-28 |
| Mary Mesnard | Nothing to disclose | Nothing to disclose | 2023-08-03 |
| Sanjay R. Mohan | Research funding: NCCN, Ichnos, Incyte, Kartos, Karyopharm, Taiho | Nothing to disclose | 2023-08-24 |
| Francesca Montanari | Nothing to disclose | Nothing to disclose | 2023-06-29 |
| Seema Nagpal | Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio | Consulting/Advisory Board: EnClear, SeaGen, Novocure Steering Committee, Nurix, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee | 2022-04-22 |
| Ryan Nguyen | Exelixis (research funding to institution) | Genomeweb (honoraria), Merck (speaker's bureau) | 2023-09-16 |
| David Noyd | Nothing to disclose | Consulting/Advisory Board: Westat | 2023-09-11 |
| Irbaz Bin Riaz | NIH/NCI | Nothing to disclose | 2023-08-10 |
| Michael K. Rooney | Nothing to disclose | Nothing to disclose | 2023-09-13 |
| Samuel R. Rubinstein | Nothing to disclose | Consulting/Advisory Board: Janssen, Sanofi, LAVA therapeutics, EUSA pharma, and Roche Diagnostics | 2022-09-10 |
| Martin Schoen | St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program | Consulting/Advisory Board: Doximity, Pfizer | 2023-08-11 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | 2023-09-11 |
| Eric K. Singhi | Nothing to disclose | Consulting/Advisory Board: AstraZeneca | 2023-08-10 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | 2023-01-29 |
| Jeremy L. Warner | AACR; NIH; Brown Physicians Incorporated | Travel: AACR; ASCO Ownership: HemOnc.org Consulting/Advisory Board: Westat, MelaxTech Editorship: ASCO |
2022-12-29 |
| Nicole M. Wood | Nothing to disclose | Consulting/Advisory Board: Westat | 2023-08-07 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
2023-10-12 |
| Travis Zack | Nothing to disclose | Nothing to disclose | 2023-09-05 |
| Marjorie Zauderer | Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. | In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. | 2023-08-08 |
| Leyre Zubiri | Nothing to disclose | Honoraria: Merck | 2022-08-22 |